Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 39%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is a leader in the transcatheter valve solutions market and has seen strong growth in its key business segments, including TAVR and TMTT. The proposed NCD from CMS is expected to remove barriers and drive higher procedure volumes, while the company's strong clinical evidence and technological leadership position it for continued growth. Additionally, EW's commitment to diversity and inclusion, multiple shots on goal with clinical works in progress, and potential for market expansion in the MR space make it a compelling investment opportunity with potential for upside in the long term.

Bears say

Edwards Lifesciences is a leader in the structural heart disease market, driven by its solid product portfolio and upcoming market-expanding catalysts. However, potential commercial hiccups, regulatory delays, product recalls, and competition pose risks to its future growth. Additionally, concerns about valve durability and lack of sustainability initiatives may weigh on investor sentiment.

Edwards Lifesciences (EW) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 39% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 18 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.